Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Clinical genetics

Understanding Your ACTN2 Diagnosis

At a Glance

ACTN2-related disease is a very rare genetic muscle condition that may affect skeletal muscles, the heart, or both. Symptoms vary widely, so care usually starts with heart and muscle testing, followed by regular monitoring and treatment based on each person’s needs.

Receiving a diagnosis of an ACTN2-related disease can feel overwhelming, especially since you may have never heard of it before and your local doctors may have limited experience with it. This is an extremely rare genetic condition that affects the way muscles are built and how they function [1][2]. Because it is so rare, there are currently no established statistics on how many people in the general population have it; most of what we know comes from small groups of families and individual case reports [2][3]. Please note that because evidence is limited to small cohorts, medical knowledge about the disease’s full range and care recommendations may evolve over time.

What is ACTN2-Related Disease?

The condition is caused by changes (variants) in the ACTN2 gene. This gene provides the instructions for making a protein called alpha-actinin-2 [4]. Think of this protein as a crucial structural anchor within your muscle cells. It helps cross-link and stabilize the fibers that allow muscles to contract and relax [4][5]. When the protein doesn’t work correctly, the internal structure of the muscle—the sarcomere—can become disorganized or unstable [6][7].

ACTN2-related disease is not a single, predictable condition. Instead, it is a spectrum that can affect different parts of the body in different ways:

  • Skeletal Myopathy: This refers to disease of the skeletal muscles (the muscles you use to move your limbs and body) [2].
  • Cardiomyopathy: This refers to disease of the heart muscle, which can affect the heart’s shape or its ability to pump blood effectively [1][8].
  • Both: Some individuals may have both skeletal muscle weakness and heart involvement [1].

A Wide Spectrum of Symptoms

One of the most challenging aspects of an ACTN2 diagnosis is the high degree of variability. Even members of the same family with the same genetic variant may experience different symptoms [2].

The phenotypes (the way the disease shows up in a person) reported in studies can range from:

  • Reduced Penetrance: Some people carry a pathogenic (disease-causing) variant but do not develop noticeable symptoms early in life, or they may remain asymptomatic [2].
  • Adult-Onset Weakness: Many patients begin to notice weakness in adulthood, often starting in the legs (distal or limb-girdle weakness) or sometimes affecting the facial muscles [2][3].
  • Congenital Myopathy: In rarer cases, severe muscle weakness and breathing difficulties are present from birth [7].
  • Heart-Only Involvement: Some variants primarily affect the heart, potentially leading to conditions like hypertrophic cardiomyopathy (thickened heart muscle) or dilated cardiomyopathy (enlarged and weakened heart muscle) [1][8].

Understanding the Rarity

If your doctor seems unfamiliar with ACTN2-related disease, it is because the medical community is still in the early stages of documenting it. There is no official “incidence rate” because the total number of confirmed cases worldwide remains very small. For example, one of the primary studies to date followed a group of only 37 people across 11 families [2]. Because these cohorts are small, they might not represent the entire spectrum of the disease.

Because it is so rare, you may need to act as an advocate for your own care, helping your medical team connect with specialists in clinical genetics, neuromuscular disorders, or cardiology focused on genetic conditions.

Managing the Unknown

While researchers are working to understand genotype-phenotype correlations—the link between a specific genetic change and the symptoms it causes—those links are not yet fully defined for most ACTN2 variants [2][1]. This means doctors cannot always predict exactly how the condition will progress.

However, the focus of medical care is on managing the specific symptoms you do have. This typically involves:

  1. Baseline Testing: Establishing how your heart and muscles are functioning right now through tools like echocardiograms (heart ultrasounds) and physical strength assessments [8][2].
  2. Ongoing Monitoring: Regular check-ups to catch any changes in heart rhythm or muscle strength early.
  3. Symptom-Specific Care: Using physical therapy for muscle weakness or standard cardiac management if the heart is affected [8].

Though the diagnosis brings many questions, your medical team can build a care plan tailored to your specific needs, focusing on maintaining function and protecting your long-term health.

Common questions in this guide

What is ACTN2-related cardiac and skeletal myopathy?
It is a very rare genetic condition caused by a change in the ACTN2 gene. The change can affect skeletal muscles, the heart, or both because ACTN2 helps make a protein that supports muscle structure.
What symptoms can ACTN2-related disease cause?
Symptoms vary widely. Some people have no noticeable symptoms, while others develop muscle weakness in the legs or face, weakness and breathing problems from birth, heart palpitations, or heart muscle disease.
Does everyone with an ACTN2 variant develop symptoms?
No. Some people with a disease-causing ACTN2 variant have few or no symptoms, and even relatives with the same variant may be affected differently. A clinical genetics specialist can help explain what is known about a specific variant.
What tests are usually needed after an ACTN2 diagnosis?
Care often begins with baseline testing to check heart and muscle function, such as an echocardiogram, or heart ultrasound, and a physical strength assessment. Regular follow-up may monitor heart rhythm and muscle strength for changes over time.
How is ACTN2-related disease managed?
Management is tailored to the problems a person has because the condition can affect the heart, skeletal muscles, or both. Physical therapy may support muscle function, while standard cardiac care may be used when the heart is involved, together with ongoing monitoring.
Can ACTN2-related disease affect more than one family member?
It can occur in more than one family member because it is caused by a change in the ACTN2 gene. A clinical genetics team can use family history and genetic results to discuss whether relatives may benefit from evaluation.

Get notified when new evidence is published on ACTN2-related cardiac and skeletal myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Mutation update for the ACTN2 gene.

    Ranta-Aho J, Olive M, Vandroux M, et al.

    Human mutation 2022; (43(12)):1745-1756 doi:10.1002/humu.24470.

    PMID: 36116040
  2. 2

    Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy.

    Iruzubieta P, Verdú-Díaz J, Töpf A, et al.

    Journal of neurology 2025; (272(2)):150 doi:10.1007/s00415-025-12893-9.

    PMID: 39812845
  3. 3

    Recurring homozygous ACTN2 variant (p.Arg506Gly) causes a recessive myopathy.

    Donkervoort S, Mohassel P, O'Leary M, et al.

    Annals of clinical and translational neurology 2024; (11(3)):629-640 doi:10.1002/acn3.51983.

    PMID: 38311799
  4. 4

    Cardiomyopathy-associated variants alter the structure and function of the α-actinin-2 actin-binding domain.

    Atang AE, Rebbeck RT, Thomas DD, Avery AW

    Biochemical and biophysical research communications 2023; (670()):12-18 doi:10.1016/j.bbrc.2023.05.050.

    PMID: 37271035
  5. 5

    Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms.

    Lindholm ME, Jimenez-Morales D, Zhu H, et al.

    Circulation. Genomic and precision medicine 2021; (14(6)):e003419 doi:10.1161/CIRCGEN.121.003419.

    PMID: 34802252
  6. 6

    Protein-extending ACTN2 frameshift variants cause variable myopathy phenotypes by protein aggregation.

    Ranta-Aho J, Felice KJ, Jonson PH, et al.

    Annals of clinical and translational neurology 2024; (11(9)):2392-2405 doi:10.1002/acn3.52154.

    PMID: 39095936
  7. 7

    ACTN2 mutations cause "Multiple structured Core Disease" (MsCD).

    Lornage X, Romero NB, Grosgogeat CA, et al.

    Acta neuropathologica 2019; (137(3)):501-519 doi:10.1007/s00401-019-01963-8.

    PMID: 30701273
  8. 8

    Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.

    Prondzynski M, Lemoine MD, Zech AT, et al.

    EMBO molecular medicine 2019; (11(12)):e11115 doi:10.15252/emmm.201911115.

    PMID: 31680489

This page is for informational purposes only and does not constitute medical advice. Your clinical genetics, neuromuscular, and cardiology teams can interpret your ACTN2 results and tailor testing and follow-up to you or your child.